Risk of cerebrovascular accident associated with use of antipsychotics: Population-based case-control study

Journal of the American Geriatrics Society

Volumn 59, Issue 7, 2011, Pages 1182-1187

  Laredo, Leonor ^a   Vargas, Emilio ^a,b   Blasco, Antonio Javier ^c   Aguilar, Maria Dolores ^c   Moreno, Alfonso ^a,b   Portolés, Antonio ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Advanced Techniques in Health Services Research (TAISS)   (Spain)

Author keywords

antipsychotic medications; atypical; cerebrovascular accident; conventional; elderly

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PROCHLORPERAZINE; RISPERIDONE; THIORIDAZINE;

AGED; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; OBESITY; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DEMENTIA; FEMALE; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; STROKE;

EID: 79960426655     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03479.x     Document Type: Article

References (34)

1. Delay J, Deniker P, Ropert R., Four years of experience with chlorpromazine in therapy of psychoses. Presse Med 1956; 64: 493-496.
2. Meyer JM., Antipsychotic safety and efficacy concerns. J Clin Psychiatry 2007; 68 (Suppl 14): 20-26.
3. Gill SS, Bronskill SE, Normand ST, et al,. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-786. (Pubitemid 351650498)
4. Gentile S., Second-generation antipsychotics in dementia: Beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology 2010; 212: 119-129.
5. Aupperle P., Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics. Am J Alzheimers Dis Other Demen 2006; 21: 101-108.
6. Carson S, McDonagh MS, Peterson K., A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 2006; 54: 354-361.
7. Trifiro G, Spina E, Gambassi G., Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59: 1-12.
8. Pierre JM., Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management. Drug Saf 2005; 28: 191-208. (Pubitemid 40364887)
9. Mathews M, Muzina DJ., Atypical antipsychotics: New drugs, new challenges. Cleveland Clinic J Med 2007; 74: 597-606.
10. Herrmann N, Lanctot KL., Atypical antipsychotics for neuropsychiatric symptoms of dementia-malignant or maligned? Drug Saf 2006; 29: 833-843. (Pubitemid 44511585)
11. Schneeweiss S, Setogouchi S, Brookhart A, et al,. Risk of death associated with the use of conventional versus antipsychotic drug among elderly patients. Can Med Assoc J 2007; 176: 627-632. (Pubitemid 46426056)
12. * (risperidone) and Cerebrovascular Adverse Events in Placebo-controlled Dementia Trials [on-line]. Available at Accessed March 13, 2009.
13. Health Canada. ZYPREXA (olanzapine) and Cerebrovascular Adverse Events in Placebo-Controlled Elderly Dementia Trials [on-line]. Available at Accessed March 13, 2009.
14. Valiyeva E, Herrmann N, Rochon PA, et al,. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: A population-based time-series analysis. Can Med Assoc J 2008; 179: 438-446.
15. US Food and Drug Administration. 2003 Safety Alert-RISPERDAL (risperidone) [on-line]. Available at Accessed March 20, 2009.
16. UK Committee on Safety of Medicines. Atypical antipsychotic drugs and stroke: Message from Professor Gordon Duff, Chair-man [on-line]. Available at Accessed April 20, 2009.
17. Mowat D, Fowlie D, MacEwan T., CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 2004; 328: 1262. (Pubitemid 38686123)
18. Smith DA, Beier MT., Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004; 5: 129-132. (Pubitemid 38380415)
19. Moretti R, Torre P, Antonello RM, et al,. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: Risks of cerebrovascular events. A controlled, open-label study. J Neurol 2005; 252: 1186-1193. (Pubitemid 41443617)
20. Barnett MJ, Wehring H, Perry PJ., Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol 2007; 27: 595-601. (Pubitemid 351339446)
21. Douglas IJ, Smeeth L., Exposure to antipsychotics and risk of stroke: Self controlled case series study. BMJ 2008; 337: a1227.
22. Finkel S, Kozma C, Long S, et al,. Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17: 617-629. (Pubitemid 41758766)
23. Gill SS, Rochon PA, Herrmann N, et al,. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ 2005; 330: 445-448. (Pubitemid 40314208)
24. Herrmann N, Mamdani M, Lanctot KL., Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-1115. (Pubitemid 38736000)
25. Liperoti R, Gambassi G, Lapane KL, et al,. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66: 1090-1096. (Pubitemid 41442273)
26. Raivio MM, Laurila JV, Strandberg TE, et al,. Psychotropic medication and stroke outcome. Am J Psychiatry 2005; 162: 1027-1028.
27. Sacchetti E, Trifiro G, Caputi A, et al,. Risk of stroke with typical and atypical anti-psychotics: A retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22: 39-46.
28. Setoguchi S, Wang PS, Alan BM, et al,. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008; 56: 1644-1650.
29. Percudani M, Barbui C, Fortino I, et al,. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 2005; 25: 468-470. (Pubitemid 41368370)
30. General Practice Research Database [on-line]. Available at Accessed April 25, 2009.
31. Office for National Statistics. Key Health statistics from general practice 1998. 2000. London, Office for National Statistics. MB6 No 2.
32. Chan M, Chong C, Wu A, et al,. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: A hospital-based, retrospective, cohort study. Int J Geriatr Psychiatry 2010; 25: 362-370.
33. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al,. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689. (Pubitemid 36539051)
34. Goldstein LB, Adams R, Alberts MJ, et al,. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council [trunc]. Circulation 2006; 13: e873-e923.